{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:15:24Z","timestamp":1792124124094,"version":"4.4.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Institute (US)","award":["P30 CA015704"],"award-info":[{"award-number":["P30 CA015704"]}]},{"name":"National Cancer Institute (US)","award":["P30 CA033572"],"award-info":[{"award-number":["P30 CA033572"]}]},{"name":"National Cancer Institute (US)","award":["R50 CA221836"],"award-info":[{"award-number":["R50 CA221836"]}]},{"name":"National Cancer Institute (US)","award":["P50 CA097186"],"award-info":[{"award-number":["P50 CA097186"]}]},{"name":"Prostate Cancer Foundation (US)","award":["Young Investigator Award"],"award-info":[{"award-number":["Young Investigator Award"]}]},{"name":"Prostate Cancer Foundation (US)","award":["Young Investigator Award"],"award-info":[{"award-number":["Young Investigator Award"]}]},{"name":"U.S. Department of Defense (US)","award":["W81XWH-16-1-0484"],"award-info":[{"award-number":["W81XWH-16-1-0484"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0198389","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T17:36:58Z","timestamp":1527874618000},"page":"e0198389","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":86,"title":["A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5510-0661","authenticated-orcid":true,"given":"Michael T.","family":"Schweizer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Haugk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u017eefa S.","family":"McKiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth F.","family":"Dumpit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannine S.","family":"McCune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Plymate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"issue":"1","key":"ref1","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"RL Siegel","year":"2018"},{"issue":"4","key":"ref2","first-page":"293","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"C Huggins","year":"1941","journal-title":"Cancer research"},{"issue":"7","key":"ref3","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"HI Scher","year":"2008","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-015-0225-2","article-title":"Persistent androgen receptor addiction in castration-resistant prostate cancer","volume":"8","author":"MT Schweizer","year":"2015","journal-title":"Journal of hematology & oncology"},{"key":"ref5","article-title":"Enzalutamide in Metastatic Prostate Cancer before Chemotherapy","author":"TM Beer","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"21","key":"ref6","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"JS de Bono","year":"2011","journal-title":"The New England journal of medicine"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"CJ Ryan","year":"2013","journal-title":"The New England journal of medicine"},{"issue":"13","key":"ref8","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"HI Scher","year":"2012","journal-title":"The New England journal of medicine"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"ES Antonarakis","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.cell.2013.07.029","article-title":"A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer","volume":"154","author":"KH Chang","year":"2013","journal-title":"Cell"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm972","article-title":"Molecular determinants of resistance to antiandrogen therapy","volume":"10","author":"CD Chen","year":"2004","journal-title":"Nature medicine"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"RB Montgomery","year":"2008","journal-title":"Cancer research"},{"issue":"18","key":"ref13","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","article-title":"Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants","volume":"17","author":"EA Mostaghel","year":"2011","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1158\/1055-9965.EPI-10-1023","article-title":"Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes","volume":"20","author":"JL Wright","year":"2011","journal-title":"Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"issue":"18","key":"ref15","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1200\/JCO.2010.31.2405","article-title":"SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer","volume":"29","author":"M Yang","year":"2011","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"6","key":"ref16","first-page":"1590","article-title":"Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clinical cancer research: an official journal of the","volume":"20","author":"Z Yu","year":"2014","journal-title":"American Association for Cancer Research"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/0008-5472.CAN-09-3950","article-title":"Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species","volume":"70","author":"Y Jin","year":"2010","journal-title":"Cancer research"},{"issue":"21","key":"ref18","first-page":"6141","article-title":"Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells","volume":"62","author":"V Grunwald","year":"2002","journal-title":"Cancer research"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm1052","article-title":"mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways","volume":"10","author":"PK Majumder","year":"2004","journal-title":"Nature medicine"},{"issue":"10","key":"ref20","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1158\/0008-5472.CAN-13-2543","article-title":"NF-kappaB gene signature predicts prostate cancer progression","volume":"74","author":"R Jin","year":"2014","journal-title":"Cancer research"},{"issue":"16","key":"ref21","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.1158\/0008-5472.CAN-08-0107","article-title":"The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth","volume":"68","author":"RJ Jin","year":"2008","journal-title":"Cancer research"},{"issue":"9","key":"ref22","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm.2890","article-title":"Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B","volume":"18","author":"Y Sun","year":"2012","journal-title":"Nature medicine"},{"issue":"8","key":"ref23","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1158\/1535-7163.MCT-13-0027","article-title":"NF-kappaB2\/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants","volume":"12","author":"N Nadiminty","year":"2013","journal-title":"Molecular cancer therapeutics"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1586\/eem.10.49","article-title":"Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer","volume":"5","author":"R Hu","year":"2010","journal-title":"Expert review of endocrinology & metabolism"},{"issue":"13","key":"ref25","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1158\/0008-5472.CAN-08-0594","article-title":"Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance","volume":"68","author":"SM Dehm","year":"2008","journal-title":"Cancer research"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","article-title":"Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer","volume":"69","author":"R Hu","year":"2009","journal-title":"Cancer research"},{"issue":"8","key":"ref27","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1172\/JCI41824","article-title":"Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant","volume":"120","author":"S Sun","year":"2010","journal-title":"The Journal of clinical investigation"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"e0146931","DOI":"10.1371\/journal.pone.0146931","article-title":"A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion","volume":"11","author":"ML Circu","year":"2016","journal-title":"PloS one"},{"issue":"12","key":"ref29","first-page":"3198","article-title":"Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clinical cancer research: an official journal of the","volume":"20","author":"C Liu","year":"2014","journal-title":"American Association for Cancer Research"},{"issue":"9","key":"ref30","doi-asserted-by":"crossref","first-page":"e7124","DOI":"10.1371\/journal.pone.0007124","article-title":"Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling","volume":"4","author":"AD Balgi","year":"2009","journal-title":"PloS one"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1038\/bcj.2011.38","article-title":"Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production","volume":"1","author":"FL Khanim","year":"2011","journal-title":"Blood cancer journal"},{"issue":"15","key":"ref32","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1158\/1078-0432.CCR-12-2895","article-title":"Anticancer effects of niclosamide in human glioblastoma","volume":"19","author":"A Wieland","year":"2013","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"550","DOI":"10.7326\/0003-4819-102-4-550","article-title":"Niclosamide therapy for tapeworm infections","volume":"102","author":"RD Pearson","year":"1985","journal-title":"Annals of internal medicine"},{"issue":"5","key":"ref34","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/QCO.0b013e3282ef579e","article-title":"Intestinal cestodes","volume":"20","author":"P Craig","year":"2007","journal-title":"Current opinion in infectious diseases"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0163-7258(82)90064-X","article-title":"The biology and toxicology of molluscicides, Bayluscide","volume":"19","author":"P Andrews","year":"1982","journal-title":"Pharmacology & therapeutics"},{"issue":"8","key":"ref36","doi-asserted-by":"crossref","first-page":"909","DOI":"10.4155\/bio.12.41","article-title":"Development of a method by UPLC-MS\/MS for the quantification of tizoxanide in human plasma and its pharmacokinetic application","volume":"4","author":"G Marcelin-Jimenez","year":"2012","journal-title":"Bioanalysis"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2307\/2531628","article-title":"Continual reassessment method: a practical design for phase 1 clinical trials in cancer","volume":"46","author":"J O'Quigley","year":"1990","journal-title":"Biometrics"},{"key":"ref38","article-title":"Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer","author":"C Liu","year":"2016","journal-title":"Oncotarget"},{"issue":"13","key":"ref39","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/pros.23015","article-title":"Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition","volume":"75","author":"C Liu","year":"2015","journal-title":"The Prostate"},{"issue":"19","key":"ref40","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","article-title":"Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide","volume":"35","author":"ES Antonarakis","year":"2017","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"ref41","article-title":"Targeting constitutively active androgen receptor splice variants in castration resistant prostate cancer","author":"MT Schweizer","year":"2016","journal-title":"Expert opinion on therapeutic targets"},{"issue":"15_suppl","key":"ref42","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.2017.35.15_suppl.5005","article-title":"Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant prostate cancer (mCRPC)","volume":"35","author":"M-E Taplin","year":"2017","journal-title":"Journal of Clinical Oncology"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0202709","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T00:00:00Z","timestamp":1534291200000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0198389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T17:28:04Z","timestamp":1589045284000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0198389"}},"subtitle":[],"editor":[{"given":"Quan Sing","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0198389","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pone.0202709","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}